Five-year follow-up data from KEYNOTE-942 underscore the continued potential of intismeran autogene (mRNA-4157 or V940) in combination with KEYTRUDA® (pembrolizumab) for patients with resected high-risk melanoma

Results from the final analysis of KEYNOTE-522, evaluating KEYTRUDA in combination with chemotherapy, demonstrate continued survival benefit for patients with high-risk early-stage triple-negative breast cancer (TNBC)

New data for sacituzumab tirumotecan (sac-TMT), an investigational TROP2‑directed antibody‑drug conjugate, add to ongoing research of novel treatment approaches for patients with non‑small cell lung cancer

Data from ASCENT-04/KEYNOTE-D19, evaluating KEYTRUDA plus Trodelvy® (sacituzumab govitecan-hziy) for patients with metastatic TNBC, will be featured in the official ASCO 2026 Press Program